 Accession No.: BL-13-M24888

Department of Pathology
Center for Advanced Molecular Diagnostics Unit Number(s): BWH 027-08-782
75 Francis Street, Boston, MA 02115 DFCI 603-76-2

Tel (857) 307-1500 Fax (857) 307-1522 Patient Name: BARRETT, KEITH J

Birth Date: 7/22/1952
Age Sex: 61 Year old Male 



 

Specimen Submitted Facility Lab Control Number/MRN Hospital Location

A. Molec Dx Fixed tissue/block BWH Doctor Office
Received Report Date Procedure Date
7/31/2013 7/31/2013

Physician (s)/Copies to:
DEBORAH SCHRAG MD,

Test Performed - MDOMAP4 B

Test Description - OncoMap 4

Accession numbers on blocks submitted - BS-13-09200

Original Pathologic Diagnosis - Colon Adenocarcinoma

Original Specimen Collection Date -

Estimated percentage of neoplastic cells in submitted specimen - 70%

CLINICAL DATA:

Clinical Diagnosis:

RESULTS

DNA VARIANTS:

BRAF c.1799T>A (p.Val600Glu, p.V600E, GTG>GAG), exon 15

INTERPRETATION:

BRAF codon 600 mutation predicts lack of response to therapy with antibodies targeted to
the epidermal grown factor receptor (e.g.cetuximab, panitumumab)

NEGATIVE for following mutations with clinical relevance for this tumor type: AKT1

STDS D'S

.EL7K, APC p.E1306*, APC p.E1309fs*4, APC p.E1309fs*6, APC p.E1379*, APC p.Q1338*, APC
.Q1367*, APC p.Q1378*, APC p.Q1429*, APC p.R1114*, APC p.R1450*, APC p.R876*, APC
.S1465fs*3, APC p.T1556fs*3, BRAF p.T599 V600insTT, EGFR p.D770_N77linsN, EGFR
.E746_A750>V, EGFR p.E746_A750del, EGFR p.E746 A750del, EGFR p.E746_S752>A, EGFR
.E746_S752>V, EGFR p.E746_T751>A, EGFR p.E746_T751del, EGFR p.E746K, EGFR p.G719A, EGFR
.G719C, EGFR p.G719D, EGFR p.G719S, EGFR p.1744_A750>VK, EGFR p.L747_A750>P, EGFR

DEBORAH SCHRAG, M.D. CLIA: 22D2040971
DFCI Laboratory Director:
ONCOLOGY Dr. Neal Lindeman

45 Brookline Ave
BOSTON, MA 02115
 




 

p.L747_A750>P, EGFR p.L747_E749del, EGFR p.L747_P753>Q, EGFR p.L747_P753>S, EGFR
p.L747_R748>FP, EGFR p.L747_S752del, EGFR p.L747_T751>P, EGFR p.L747_1751>S, EGFR
p.L747_T751del, EGFR p.L858R, EGFR p.L858R, EGFR p.L858R, EGFR p.L861Q, EGFR
p.N771_P772>SVDNR, EGFR p.P772_H773insV, EGFR p.S752_I759del, EGFR p.S768I, EGFR p.T790M,
EGFR p.V769_D770insASV, EGFR p.V769 D770insASV, KRAS p.A146T, KRAS p.A59T, KRAS p.G12A,
KRAS p.G12C, KRAS p.G12D, KRAS p.G12R, KRAS p.G12S, KRAS p.G12V, KRAS p.G13A, KRAS
p.G13C, KRAS p.G13D, KRAS p.G13R, KRAS p.G13S, KRAS p.G13V, KRAS p.L19F, KRAS p.L19F,
KRAS p.Q22K, KRAS p.Q61E, KRAS p.Q61H, KRAS p.Q61H, KRAS p.Q61K, KRAS p.Q61L, KRAS
p.Q61P, KRAS p.Q61R, MLH1 p.V384D

The following assays did not yield satisfactory results:
STK11_P281L

TEST INFORMATION

Background:

Somatic mutations in oncogenes and tumor-suppressor genes contribute to the
pathogenesis and evolution of human cancers. These alterations can provide prognostic and
predictive information and stratify cancers for targeted therapeutic information.

Method:

We have developed a multiplexed assay to detect somatic mutations in tumor DNA
extracted from fresh, frozen or formalin-fixed paraffin-embedded samples. The assay
OncoMap 4 detects mutations in 472 different loci from 41 cancer genes. DNA is isolated
from tissue containing at least 50% tumor nuclei and analyzed by multiplex PCR
amplification of the region containing the nucleotide variant of interest, an optimized
primer extension reaction to generate allele-specific DNA products, and chip-based mass
spectrometry for separation and analysis of the DNA analytes (Sequenom MassARRAY 4). The
41 genes are: ABL1, AKT1, AKT2, APC, BRAF, CDK4, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2,
FGFR1, FGFR2, FGFR3, FLT3, GNAl11, GNAQ, GNAS, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, KRAS,
MAP2K1, MET, MLH1, MYC, NPM1, NRAS, PDGFRA, PIK3CA, PIK3R1, PTEN, RB1, RET, SRC, STK11,
TP53, VHL. A full listing of the loci tested can be found at )PCMP, or by contacting the
Center for Advanced Molecular Diagnostics (857-307-1500).

These tests were developed and their performance characteristics determined by the
, . They have not been
cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that
such clearance or approval is not necessary.

REFERENCES:

Di Nicolantonio, F et al. Wild-type BRAF is required for response to panitumumab or
cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 26:5705

By his/her signature below, the senior physician certifies that he/she personally
reviewed all the laboratory data of the described specimen(s) and rendered or confirmed
the diagnosis(es) related thereto.
